
BiomX Inc. (PHGE) Stock Forecast & Price Target
BiomX Inc. (PHGE) Analyst Ratings
Bulls say
BiomX Inc. is advancing its therapeutic product candidates, specifically BX211 and BX011, which have demonstrated positive clinical outcomes that indicate significant potential in treating diabetic foot osteomyelitis and chronic pulmonary infections. The favorable trends observed in the Phase 2 trial results for BX211, coupled with the positive FDA feedback for BX011's advancement into a Phase 2a study, suggest a pathway for enhanced market penetration and expansion into additional therapeutic indications. Furthermore, the potential for broadening valuation metrics internationally, alongside ongoing dialogue with the FDA, underscores an optimistic outlook for future growth and profitability in BiomX's innovative treatment solutions.
Bears say
BiomX Inc faces a negative outlook primarily due to the results of its recent clinical trials, where key endpoints narrowly missed statistical significance, particularly the week 13 PAR, which could undermine investor confidence. Additionally, the company may struggle to secure sufficient funding necessary for advancing its drug pipeline, compounded by the potential of dilutive capital raises that would adversely affect existing shareholder equity. Furthermore, uncertainty remains regarding the commercial viability of its therapies, which adds to the overall risk profile and impacts market sentiment negatively.
This aggregate rating is based on analysts' research of BiomX Inc. and is not a guaranteed prediction by Public.com or investment advice.
BiomX Inc. (PHGE) Analyst Forecast & Price Prediction
Start investing in BiomX Inc. (PHGE)
Order type
Buy in
Order amount
Est. shares
0 shares